Troriluzole failed a phase 3 trial in spinocerebellar ataxia in 2022. Based on talks with the FDA, Biohaven kept tracking ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

Courtney Walker, Chief Growth Officer at MMC and RXMosaic, discusses the evolving role of communicators and the future of the healthcare industry. AI will significantly transform the field, ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Masimo’s long-running proxy fight has come to a close, at least for now. | Masimo’s long-running proxy fight has come to a ...

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run ...

After CEO Kevin Lobo promised earlier this summer a “bullish” M&A pipeline, Stryker is following through with its seventh ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...